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Abstract
Background: Breast cancer is one of the main health problems in developed countries, occupying
first place in mortality in women. It is well-known that there are risk factors associated with breast
cancer development. Nonetheless, in 50–80% of cases known risk factors have not been identified,
this has generated the attempt to identify new factors related with this neoplasia as viral infections.
The aim of this work is investigate the prevalence of HPV DNA in patients with breast lesions at
the Instituto Nacional de Cancerologia de Mexico.
Methods: Fifty-one cases of breast cancer were selected from the files of the institute and
compared by age and tumor size with 43 cases of non malignant breast lesions (fibroadenoma,
fibrocystic disease and phyllodes tumor). Paraffin embedded specimens were selected, HPV DNA
was analyzed by polymerase chain reaction (PCR) and sequenced for different types of HPV in case
of positivity for HPV-DNA. Descriptive analysis of clinical and pathological variables was performed
and comparisons between positive and negative cases was done.
Results: All patients were mexican, mean age was 53.3, median age of menarche was 13 and
median tumor size 9 cms. Cervicovaginal cytology was performed to all patients, 1 patient (1.9%)
of cancer group had HPV and none in the other group, no cases were diagnosed with cervical
dysplasia. In the group of carcinomas 36 (70.5%) were negative and 15 (29.4%) were positive to
HPV-DNA, 10(66.6%) were positive for HPV 16, 3(20%) for HPV 18, two cases (13.4%) were
positive for both. In the group of benign conditions all were negative to HPV-DNA.
Conclusion: Presence of HPV in breast cancer in our group of cases is high in comparison to other
authors; larger numbers of cases need to be analyzed in order to establish the exact role of this
virus in the pathogenesis of breast cancer.
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Background
In developing countries, breast cancer occupies second
place in frequency, preceded only by cervical cancer, as
has been observed in reports on Mexico [1]. Worldwide,
breast cancer is one of the main health problems in devel-
oped countries, occupying first place in mortality in
women [2].
Breast cancer in Mexico continues to be one of the princi-
pal health problems for feminine population. In the year
2003, the Mexican General Epidemiology Directorate
reported 12,433 (11.3%) new cases of invasive breast can-
cer and 517 (0.4%) cases of cancer in situ, presenting a
mortality rate of 7.43/100,000 inhabitants [3].
It is well-known that there are risk factors associated with
breast cancer development (age, familial history, personal
history of breast cancer). Nonetheless, in 50–80% of cases
known risk factors have not been identified, which has
generated the attempt to identify new factors related with
this neoplasia[1].
Recent studies suggest the association of viral infections
with breast cancer pathogenesis, such as Epstein-Barr virus
(EBV) [4] and mouse mammary tumor virus (MMTV) [5].
In addition, human papilloma virus (HPV) DNA
sequences have been isolated. The relationship of HPV
with other neoplasms in other anatomic sites (anogenital,
upper aerodigestive tract, and skin) is well-known. There-
fore, we know that HPV is related with 99.7% of cervi-
couterine carcinomas, and that there exist specific types
that are associated with pre- and malignant cervical
lesions [6].
Correlation of DNA identification of HPV and breast can-
cer ranges in variability from 0–86% of cases [7], and
moreover, this has not been related with anogenital
pathology. To date, the mechanism by which the virus
reaches the breast has not been clearly identified [8].
At present, studies evaluating the presence of HPV in
mammary lesions have practically all been conducted in
Europe and Asia; we have identified two carried out in the
U.S. [9,10] and one in Brazil [8].
We conducted this retrospective study with a representa-
tive number of malignant and non epithelial breast
lesions in order to investigate the frequency of HPV in
both types of tumors in a group of population different to
the ones studied by others.
Methods
Patients and specimen collection
All patients were selected from the clinical archives at the
Instituto Nacional de Cancerología de México. Cases
selected from January 1999 to December 2003 in whom
complete information from the chart was available were
eligible for further evaluation.
From all cases evaluated in our institution 65 were cho-
sen, slides and paraffin blocks located and reviewed by
two pathologist, the diagnosis of breast cancer was con-
firmed. Most representative blocks were selected for HPV
typing.
Clinical information was retrieved from the clinical file,
such as: Age at diagnosis, age of menarche, family history
of breast cancer, previous history of tobacco use, cancer
stage, tumor size, histology, grade of tumor, Scarff-Bloom-
Richardson (SBR) grading, estrogen receptors and proges-
terone receptors status. Forty three cases of non malignant
breast lesions were used as controls (17 phyllodes tumors,
14 fibroadenoma and 12 fibrocystic disease).
DNA isolation and HPV typing were performed at the
Molecular Laboratory at Sikl's Department of Pathology
Medical Faculty Hospital, Charles University, Plzen,
Czech Republic.
Data analysis was performed with SPSS 15.0 for windows
(SPSS Inc, USA). Descriptive analysis of clinical and path-
ological variables was performed and comparisons
between positive and negative cases were by chi-square
test and student-t  when appropriate. Statistical signifi-
cance was accepted at the 5% level. To obtain a power of
at least 80% a sample size was calculated and a minimum
of 45 cases must be evaluated for comparisons. This pro-
tocol was evaluated and approved by the internal review
board of both institutions.
DNA isolation
Five 5-μm-thick sections were cut from FFPE tissue. After
every sample, the knife was cleaned with xylene and etha-
nol. Negative controls consisted of extracted 5-μm-thick
slices of paraffin blocks containing no tissue and cut in
between the tissue samples. DNA was extracted by the
DNeasy Tissue Kit (QIAGEN, Hilden, Germany) accord-
ing to manufacturer's protocol. Quality of isolated DNA
was checked by PCR of control genes with primers gener-
ating fragments of 100, 200, 300, 400, and 600 bp [11].
HPV PCR systems
According to the quality of DNA different PCR systems for
HPV detection and typing were used. If there was possible
to amplify more than 400 bp fragment of control genes
from DNA of sample (27 samples), nested PCR using
MY09/11 and GP5+/6+ was performed. Degenerated
primers MY09 (5'CGTCCMARRGGAWACTGATC 3') and
MY11 (5'GCMCAGGGWCATAAYAATGG 3') [12] amplify
450 bp long fragment in highly conserved region in L1BMC Cancer 2009, 9:26 http://www.biomedcentral.com/1471-2407/9/26
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gene. Consensus primers GP5+ (5'-TTTGTTACTGTGGTA-
GATACTAC-3') and GP6+ (5'-CTTATACTAAATGT-
CAAATAAAAA-3') [13] generate 140 to 150 bp fragment
of the L1 region of the virus. Both systems of primers
detect a broad spectrum of oncogenic and nononcogenic
mucosal and some mucocutaneous HPV types.
In the case of samples, where control genes were amplifi-
able in range 100–200 bp only (14 samples), the one-step
PCR with primers GP5+/6+was used. In samples of even
worse quality of DNA (10 Samples) an INNO-LiPA HPV
Genotyping kit (Innogenetics NV, Ghent, Belgium) were
used. The INNO-LiPA HPV Genotyping kit permits ultra-
sensitive detection of a broad spectrum of HPV genotypes
by PCR with primers SPF10 that amplifies a 65 bp long
region in the HPV L1 gene, and typing by a reverse hybrid-
ization (LiPA) [14].
HPV detection
Reaction mixture (50 μl) for nested PCR consisted of 1×
reaction buffer (Promega), 4 mM MgCl2, dNTPs 0.2 mM
of each, primers MY09/11 0.5 pmol each, 2.5 U Taq
polymerase (Promega) and 5 μl of isolated DNA. 3 μl of
PCR product from first step were added into reaction mix-
ture with GP5+/6+ primers, which had identical composi-
tion as in first step except for 3.5 mM MgCl2. PCRs were
run using folloving profile: initial denaturation at 95°C
for 5 min, 40 cycles of 95°C for 1 min, either 50°C
(annealing for MY09/11 primers) or 40°C (GP5+/6+
primers) for 1 min and 72°C for 1 min, final incubation
by 72°C for 5 min. In each reaction positive control (HPV
positive clinical sample from cervical smear, in which the
HPV 16 was confirmed by sequencing) and negative con-
trol were included. Negative controls were never found to
be positive. PCRs were run on the cycler GeneAmp PCR
system 2400 (PE/Applied Biosystems, Foster City, CA).
Products of all PCRs were separated in a 2% agarose gel
(Agarose for DNA electrophoresis, Serva, Heidelberg, Ger-
many). Successfully amplified PCR products were purified
with a QIAquick spin PCR purification kit (QIAGEN),
sequenced using a Big Dye Terminator Sequencing kit
(PE/Applied Biosystems), and run on an automated
sequencer ABI Prism 310 (PE/Applied Biosystems) at a
constant voltage of 11.3 kV for 20 minutes. Results were
evaluated by BLAST program http://www.ncbi.nlm.
nih.gov/BLAST.
Inno-LiPA genotyping was performed according to manu-
facturer's protocol.
Results
Of 65 patients selected per group of breast cancer, 51 spec-
imens showed DNA integrity by control genes amplifica-
tion, mean age was 53.3 ± 13.2 years (range 27–82), age
of menarche 12.9 ± 1.4 years (range 10–16), 66% (42) of
patients did not have family history of breast cancer, of
the patients with family history of breast cancer 12 (18%)
had at least one family member with the disease, only
16.9% of patients (11) were smokers. Cervicovaginal
cytology was performed to all patients, 1 patient (1.9%) of
cancer group had HPV and none in the other group, no
cases were diagnosed with cervical dysplasia.
Forty-eight tumors (94.1%) were ductal carcinomas,
tumor size ranged 1–17 cms (mean 9.4 cms), 11 tumors
(16.9%) were SBR 8 and 10 tumors (15.4%) were SBR 9.
Estrogen receptors were positive in 15 cases (23%) and
progesterone receptors were positive in 16 (24.6%).
Fifteen cases were HPV positive (29.4%) and 36 cases
(70.5%) were negative, when typing was performed, 10
(66.6%) were positive for HPV 16, 3 (20%) for HPV 18,
and two cases (13.3%) were positive for HPV 16 and 18.
(Fig 1)
When comparisons between HPV positive and negative
were done in relation to all clinical and pathological vari-
ables the only one which was significant was tumor size,
since only one tumor larger than 4 cms was positive for
HPV (p = 0.008), as shown in Table 1.
All non-malignant breast lesions were negative for HPV.
Discussion
The majority of molecular events in the genesis of breast
cancer are unknown. However, initial studies have
reported an association of breast cancer with cervical
intraepithelial neoplasia III (CIN III)-like lesions [9].
These studies have aroused interest in the search for HPV
as part of breast cancer genesis.
In 1992, Di Lonardo and colleagues were the first to dem-
onstrate the association of HPV in 29.4% of 17 patients
with breast cancer, identifying HPV 16 DNA by means of
PCR [15]. In 1999, Yu et al. in a study group of 72 patients
published on the association between HPV 33 and breast
cancer in an Oriental population (China and Japan), sug-
gesting the presence of HPV 33 DNA in invasive ductal
carcinoma (IDC) in 34.1% of patients studied and in 5%
of benign lesions, orienting thought toward its participa-
tion in the pathogenesis of breast cancer, but not for other
serotypes [16].
Hennig et al. reported the association of HPV 16 in 19 of
41 breast carcinomas (46%) in patients with a history of
CIN III lesions. HPV 16 DNA was detected in cervical
lesion in 32 of 38 patients with CIN III (84%). All patients
with HPV 16 positive for breast cancer corresponded to
the same patients with HPV 16 in CIN III lesions; there
were no cases with HPV 11, 18, or 33. HPV 16 wasBMC Cancer 2009, 9:26 http://www.biomedcentral.com/1471-2407/9/26
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detected in primary breast tumors, as well as in lymph
node metastases, in addition to a case of distant breast
cancer metastasis with HPV 16 to colon. There was no cor-
relation with the histology of breast tumor, tumor size, or
lymphatic affectation, but a slight association was demon-
strated between p53 and -21 expression in patients with
breast cancer and HPV 16 [17]. Hormonal receptors were
quantified, but no statistically significant difference was
found [18], this finding is similar to ours.
Yu in 2000 again published the correlation of HPV DNA
in 14 of 32 (43.8%) cases of patients with intraductal car-
cinoma, finding HPV 33 (but not HPV 16 or 18) DNA in
the positive cases. They suggested that HPV 33-associated
infection had a place in the pathogenesis of breast cancer
in the study population [19].
Liu et al. reported a considerable number of HPV-related
mammary lesions. They identified protein E6 and -7 in six
of 17 (35%) cases of patients with breast cancer. Cloned
HPV sequences identified DNA in serotypes 16, 18, and
probably 11, concluding that the same changes in p53
and -21 in cervix can be produced in breast, thus suggest-
ing the mechanism by means of which HPV can exert an
influence on the genesis of breast cancer [9].
Damin and colleagues detected HPV in 25 of 101
(24.75%) patients with breast cancer, and did not identify
HPV in any of the 41 benign lesions studied (20 patients
reduction mammoplasty and 21 with mammary fibroad-
enomas). In 14 (56%) patients, the authors isolated HPV
16 DNA, in 10 (40%) patients HPV 18, and in one patient
(4%) both serotypes, this study with the highest case
number [8].
Our results are similar to those reported in the world liter-
ature, in which a prevalence of between 24 and 46% is
reported in the association of invasive breast cancer and
HPV-related infection [8,9,15-20]. In our study group, we
identified HPV-positive tumors in 29.4% of cases
included in the study. HPV 16 DNA was most frequently
found (66.6%), as reported by other studies [9,15,17-20],
in which Western populations were included; the DNA of
other serotypes was not identified in this study group. We
are aware of some possible discrepancies between analyt-
ical sensitivity of the used PCR approaches even with the
special precautions to avoid minimal contamination that
we had; these possible discrepancies between the two
techniques might be the main limitation of our results.
We found no viral DNA presence in any benign lesions
and in any phyllodes tumors included in our series.
Other authors found no association between HPV pres-
ence and breast cancer, as is the case of Lindel [21], who
found no viral DNA in a group of 81 cases of breast can-
cer.
In our series, tumor size was the sole statistically signifi-
cant value, showing that the greater the lesion size, the
greater the probability of finding viral DNA in the tumor
sample but not larger than 4 cms where viral DNA seems
to be lost or could not be apprised or retrieved. Neverthe-
Electroforetical analysis of nested PCR products Figure 1
Electroforetical analysis of nested PCR products. In left line – MW marker, lines marked 34 – 49 are negative and posi-
tive samples, PCR product size 150 bp, + – positive control (described in protocol), 0,0 – double negative control (PCR 
premix with no DNA).BMC Cancer 2009, 9:26 http://www.biomedcentral.com/1471-2407/9/26
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less, this was no able to be correlated with histologic grade
or with any poor prognosis factor, which is similar to the
results of Kan et al. [16]; in these, while 48% were positive
for HPV 18 a correlation was unable to be demonstrated
with other pathologic variables or with patient outcome.
As reported by other authors for cancer – and even breast
cancer – at other localizations, expression of protein E6
and -7 was related with changes in p53 and -21, producing
apoptosis inhibition, thus favoring cellular proliferation
as part of breast cancer pathogenesis [17]. Although the
mechanism by which HPV reaches the mammary gland is
not clear, the possibility has been suggested by some
authors of a viremia, explaining HPV installation in other
organs including breast [20].
Notwithstanding this, it is important to consider the pos-
sibility of other epidemiologic factors, such as the geo-
graphic site from which cases were taken and HPV
infection prevalence, to be able to determine HPV distri-
bution in malignant breast lesions.
Conclusion
The origin of breast cancer is multifactorial. The fact that
we have not found viral DNA in benign lesions supports
to a certain extent the etiologic role of the virus in at least
a sub-population of patients. The mechanism involved is
not clear. Thus, it is necessary to include a greater number
of cases to determine the true role of the virus in the gen-
esis of these lesions and in Mexican population were this
neoplasm is a health problem research in this area is very
important, therefore, a study like this, opens another pos-
sible explanation for the development of the disease.
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